Veraxa Biotech AG - Post de-SPAC Insider Ownership | VRXA

Insider Holdings by Owner

5.82Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

39.92%

Shares Held by Insiders

5.78Mn

filed for Sep 2026

Shares Outstanding

14.47Mn

14,474,974 shares

Direct Holdings

5.00K

Indirect: 5.77Mn

Net Shares Traded (QoQ)

0

no net change in Sep 2026

Insiders Holding Shares

3

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 22, 2026

Across the past 12 months, open-market trades by Veraxa Biotech AG - Post de-SPAC insiders were all purchases, totaling $115,350 (85K shares).

Veraxa Biotech AG - Post de-SPAC's open-market purchases in the past 12 months came from 3 insiders; no insider sold.
Among Veraxa Biotech AG - Post de-SPAC's insiders, Oliver Rolf Baumann (Director) was the largest open-market buyer over the past 12 months, purchasing $75,000 of stock (50K shares), most recently on August 27, 2026.
The latest open-market trade in VRXA stock by an insider was a purchase of 30K shares for $32,700 by Christoph Samuel Ziegler (Director) on October 20, 2026.
Per Business Quant data, Veraxa Biotech AG - Post de-SPAC insiders hold 5.82Mn shares in total based on their latest Form 4 filings.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 99.26% (5.77Mn shares) of Veraxa Biotech AG - Post de-SPAC's insider total, with the other 0.74% (42.93K shares) held directly.
Holdings in Veraxa Biotech AG - Post de-SPAC stock are reported by 3 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
Veraxa Biotech AG - Post de-SPAC's top three insider holders by shares held are Oliver Rolf Baumann (Director, 5.77Mn shares), Christoph Samuel Ziegler (Director, 37.93K shares) and Christoph Rudiger Antz (Chief Executive Officer, 5K shares).
Of the shares held by VRXA insiders, 99.26% belong to Oliver Rolf Baumann.
In the past year, 3 insiders of Veraxa Biotech AG - Post de-SPAC submitted 3 Form 4 filings reporting trades, awards or other transactions.
The insider holdings and trades above for Veraxa Biotech AG - Post de-SPAC reflect Form 4 filings through October 21, 2026.

Form 4 Holdings

Insiders Holding VRXA

Insiders 3

Shares held 5.82Mn

Of outstanding 40.18%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Oliver Rolf Baumann	Director	0	5,773,618	5,773,618	99.3%	31 Aug, 2026
2	Christoph Samuel Ziegler	Director	37,932	0	37,932	0.7%	21 Oct, 2026
3	Christoph Rudiger Antz	Chief Executive Officer	5,000	0	5,000	0.1%	31 Aug, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

3 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
20 Oct, 2026	Christoph Samuel Ziegler	Director	Acquired P	30,000	$1.09	$32.70K	37,932	Direct
27 Aug, 2026	Christoph Rudiger Antz	Chief Executive Officer	Acquired P	5,000	$1.53	$7.65K	5,000	Direct
27 Aug, 2026	Oliver Rolf Baumann	Director	Acquired P	50,000	$1.50	$75.00K	5,773,618	Indirect

Veraxa Biotech AG - Post de-SPAC VRXA Insider Ownership